Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: TBL 12 Clear all

Conditions: Erectile Dysfunction, Benign Prostatic Hyperplasia
Interventions: Tadalafil, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 17
States / cities: Anchorage, Alaska • Phoenix, Arizona • La Mesa, California + 14 more

Conditions: Bulimia Nervosa, Binge Eating, Eating Disorders, Binge-Eating Disorder
Interventions: Drospirenone-Ethinyl Estradiol Oral Tablet; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Atrial Fibrillation
Interventions: Chloroquine Phosphate; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Ankylosing Spondylitis
Interventions: Tofacitinib 2 mg, Tofacitinib 5 mg, Tofacitinib 10 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 22
States / cities: Indian Wells, California • Palm Desert, California • Clearwater, Florida + 15 more

Conditions: Healthy
Interventions: TLL018 tablet, placebo; Drug
Lead sponsor: TLL Pharmaceutical, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Prostate Cancer
Interventions: Metformin, OPC; Drug · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias, Prediabetic State
Interventions: Chloroquine, Placebo Comparator; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Depressive Disorder, Major
Interventions: Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20 mg/day, Placebo; Drug · Other
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 42
States / cities: Dothan, Alabama • Tucson, Arizona • Little Rock, Arkansas + 37 more

Conditions: Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer
Interventions: cabozantinib, atezolizumab; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 914 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 57
States / cities: Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more

Conditions: Insomnia, Attention Deficit Hyperactivity Disorder
Interventions: eszopiclone, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 73
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 56 more

Conditions: Alpha 1-Antitrypsin Deficiency, Emphysema, COPD
Interventions: Placebo Oral Tablet, Alvelestat oral tablet - dose 1, Alvelestat oral tablet - dose 2; Drug
Lead sponsor: Mereo BioPharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 4
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 1 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Ceralasertib, Olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Chronic Graft Versus Host Disease
Interventions: Belumosudil; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fibromyalgia
Interventions: TNX-102 SL Tablet, 5.6 mg, Placebo SL Tablet; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 33
States / cities: Phoenix, Arizona • Oceanside, California • Santa Ana, California + 30 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Reldesemtiv, Placebo; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 47
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 41 more

Conditions: Chorea Associated With Huntington Disease
Interventions: SD-809; Drug
Lead sponsor: Auspex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 34
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 30 more

Conditions: Resistant Hypertension
Interventions: Placebo, TBC3711; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 12
States / cities: Birmingham, Alabama • Mobile, Alabama • Atlanta, Georgia + 9 more

Conditions: Chronic Kidney Disease, Dialysis, Hyperphosphatemia
Interventions: MCI-196, Placebo; Drug
Lead sponsor: Tanabe Pharma Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 38
States / cities: Glendale, Arizona • Tempe, Arizona • Hot Springs, Arkansas + 35 more

Conditions: Smoking Cessation, Alcohol Drinking
Interventions: Chantix, Behavioral Counseling Sessions, NicodermCQ, Placebo; Drug · Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 85 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cognitive Dysfunction, Memory Impairment
Interventions: Donepezil 5 mg, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 278
States / cities: Anaheim, California • Antioch, California • Baldwin Park, California + 206 more

Conditions: Irritable Bowel Syndrome With Diarrhea
Interventions: Ibodutant 10 mg, Placebo; Drug
Lead sponsor: Menarini Group; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 65
States / cities: Huntsville, Alabama • Sherwood, Arizona • Little Rock, Arkansas + 56 more

Conditions: Recurrent Urinary Tract Infection, Hypoestrogenism
Interventions: Estring Vaginal Product, Vagifem, Estrace 0.01% Vaginal Cream; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Orange, California

Conditions: Acute Myeloid Leukemia
Interventions: Entospletinib, Daunorubicin, Cytarabine, Decitabine, Azacitidine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 14
States / cities: Los Angeles, California • Chicago, Illinois • Maywood, Illinois + 10 more

Conditions: HIV, HIV Infections
Interventions: E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 872 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 79
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 54 more

Search by objective public record fields.

A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia

Binge Eating & Birth Control

Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study

Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of TLL018, With Food Effect, in Healthy Participants

Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia

A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia

A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Alternatives for Reducing Chorea in Huntington Disease

A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.

A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia

Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation

Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections

Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)

Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults